Loading...
Market
Which region will receive significant LC16m8 vaccine donations after DRC by end of 2025?
2
World Health Organization•WHO•Japan•KM Biologics•Meiji Group•Jynneos•Bavarian Nordic•ACAM2000•Emergent BioSolutions•Democratic Republic of Congo•DRC
Resolution / Starting Odds
Africa • 25%
South America • 25%
Asia • 25%
Other • 25%
WHO reports or announcements from Japan's Ministry of Foreign Affairs
Story
WHO Approves Japan's LC16m8 Vaccine for Emergency Use Against Mpox; Japan to Donate 3M Doses
Nov 19, 2024, 09:31 PM
The World Health Organization (WHO) has granted emergency use listing to Japan's LC16m8 mpox vaccine, developed by KM Biologics, a subsidiary of the Meiji Group. This approval marks the second mpox vaccine to receive WHO's emergency use authorization, following Jynneos by Bavarian Nordic and ACAM2000 by Emergent BioSolutions. The listing facilitates the use of the vaccine, especially in regions like the Democratic Republic of Congo (DRC), where Japan has committed to donating 3 million doses. The vaccine is particularly beneficial for younger children who are vulnerable to infections from household contact.
View original story
Similar markets
Africa • 25%
Asia • 25%
South America • 25%
Other • 25%
United States • 25%
Japan • 25%
China • 25%
Other • 25%
Japan • 25%
United States • 25%
Both equally • 25%
Other • 25%
Less than 200,000 • 25%
200,000 to 300,000 • 25%
300,001 to 400,000 • 25%
More than 400,000 • 25%
Kinshasa • 25%
Katanga • 25%
Kasaï • 25%
Other • 25%
Less than 50,000 • 25%
50,000 - 100,000 • 25%
100,001 - 150,000 • 25%
More than 150,000 • 25%
Yes • 50%
No • 50%
Nigeria • 25%
Kenya • 25%
South Africa • 25%
Other • 25%
Hospitals • 25%
Mobile clinics • 25%
Community centers • 25%
Other • 25%
Democratic Republic of the Congo • 25%
Kenya • 25%
Uganda • 25%
Other • 25%